Deutsche Bank
VYNE icon

Deutsche Bank’s VYNE Therapeutics VYNE Stock Holding History

Deutsche Bank’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,680
Closed -$169K – 4699
2021
Q2 		$169K Buy
2,680
+1,368
+104% +$108K ﹤0.01% 3878
2021
Q1 		$162K Sell
1,312
-123
-9% -$17.8K ﹤0.01% 3745
2020
Q4 		$163K Buy
1,435
+420
+41% +$52.8K ﹤0.01% 3579
2020
Q3 		$121K Buy
1,015
+330
+48% +$38.5K ﹤0.01% 3459
2020
Q2 		$86K Buy
685
+267
+64% +$36.2K ﹤0.01% 3524
2020
Q1 		$81K Buy
418
+23
+6% +$7.21K ﹤0.01% 3337
2019
Q4 		$131K Sell
395
-12
-3% -$4K ﹤0.01% 3452
2019
Q3 		$130K Sell
407
-249
-38% -$80.4K ﹤0.01% 3412
2019
Q2 		$282K Buy
656
+466
+245% +$231K ﹤0.01% 3638
2019
Q1 		$106K Sell
190
-222
-54% -$107K ﹤0.01% 4284
2018
Q4 		$121K Sell
412
-146
-26% -$65.4K ﹤0.01% 4134
2018
Q3 		$396K Buy
558
+361
+183% +$223K ﹤0.01% 3905
2018
Q2 		$115K Buy
197
+82
+71% +$63.7K ﹤0.01% 4501
2018
Q1 		$310K Buy
+115
New +$280K ﹤0.01% 3972

Other funds holding VYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deutsche Bank's VYNE Position: Q3 2021 in Review

Deutsche Bank sold out of VYNE Therapeutics (VYNE) in Q3 2021, closing a stake of 2,680 shares — an estimated $169K sold.

Deutsche Bank first reported a position in VYNE in Q1 2018 and held it in 14 quarters. The position peaked at $396K in Q3 2018. 64 funds tracked by Wall St. Rank hold VYNE as of Q3 2021.

  • Deutsche Bank reported no remaining VYNE Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Deutsche Bank sold 2,680 VYNE Therapeutics shares in Q3 2021, an estimated $169K.
  • Deutsche Bank first reported a position in VYNE Therapeutics in Q1 2018 and held it in 14 quarters.
  • Deutsche Bank's VYNE Therapeutics position peaked at $396K in Q3 2018.
  • 64 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q3 2021.

Based on Deutsche Bank's 13F filing for Q3 2021, filed 4 Nov 2021.